tiprankstipranks
Wave Life Sciences (DE:0VS)
FRANKFURT:0VS
Germany Market
0VS
Wave Life Sciences
RESEARCH TOOLSreports

Wave Life Sciences (0VS) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

0VS Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Wave
Life Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0VS Stock 12 Month Forecast

Average Price Target

€15.10
▲(209.37% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is €15.10 with a high forecast of €22.30 and a low forecast of €10.29. The average price target represents a 209.37% change from the last price of €4.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","8":"€8","13":"€13","18":"€18","23":"€23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.303047,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.097447200000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€15.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.293714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8,13,18,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.72,6.072542076923076,7.425084153846154,8.77762623076923,10.130168307692308,11.482710384615384,12.83525246153846,14.187794538461539,15.540336615384614,16.892878692307693,18.24542076923077,19.597962846153845,20.95050492307692,{"y":22.303047,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.72,5.518265169230769,6.316530338461538,7.114795507692308,7.913060676923077,8.711325846153848,9.509591015384615,10.307856184615385,11.106121353846156,11.904386523076925,12.702651692307693,13.500916861538464,14.29918203076923,{"y":15.097447200000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.72,5.148747230769231,5.577494461538461,6.006241692307692,6.434988923076923,6.863736153846153,7.292483384615384,7.721230615384615,8.149977846153845,8.578725076923076,9.007472307692307,9.436219538461538,9.864966769230769,{"y":10.293714,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€22.30Average Price Target€15.10Lowest Price Target€10.29
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:0VS
Alec Stranahan
Bank of America Securities
Bank of America Securities
€14.58
Buy
198.83%
Upside
Reiterated
08/12/26
Alec Stranahan Maintains Buy Rating on Wave Life Sciences with Unchanged $17 Price Target Amid Multiple Clinical Catalysts
Mizuho Securities Analyst forecast on DE:0VS
Salim Syed
Mizuho Securities
Mizuho Securities
€23.16→€19.73
Buy
304.30%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Acurx Pharmaceuticals (NASDAQ: ACXP)
Mizuho Securities Analyst forecast on DE:0VS
Mara Goldstein
Mizuho Securities
Mizuho Securities
€30.88→€22.3
Buy
357.03%
Upside
Reiterated
08/03/26
Wave Life Sciences price target lowered to $26 from $36 at Clear StreetWave Life Sciences price target lowered to $26 from $36 at Clear Street
H.C. Wainwright Analyst forecast on DE:0VS
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€11.15
Buy
128.51%
Upside
Reiterated
07/31/26
Analyst Reiterates Buy on Wave’s WVE-007, Maintaining Unchanged $13 Price Target Amid Enhanced Phase 2a INLIGHT Design
Truist Financial Analyst forecast on DE:0VS
Danielle Brill
Truist Financial
Truist Financial
€12.87
Buy
163.67%
Upside
Reiterated
07/31/26
Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
B. Riley Securities Analyst forecast on DE:0VS
Madison Elsaadi
B. Riley Securities
B. Riley Securities
€26.59→€18.87
Buy
286.72%
Upside
Reiterated
07/31/26
B. Riley Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
Citi Analyst forecast on DE:0VS
Samantha Semenkow
Citi
Citi
€20.59→€16.3
Buy
233.98%
Upside
Reiterated
07/31/26
Wave Life Sciences price target lowered to $19 from $24 at CitiWave Life Sciences price target lowered to $19 from $24 at Citi
Wedbush Analyst forecast on DE:0VS
Yun Zhong
Wedbush
Wedbush
€12.87→€10.29
Buy
110.94%
Upside
Assigned
07/31/26
Wedbush Releases a Buy Rating on Wave Life Sciences (WVE)
Wells Fargo Analyst forecast on DE:0VS
Benjamin Burnett
Wells Fargo
Wells Fargo
€12.01
Buy
146.09%
Upside
Reiterated
07/30/26
Wells Fargo Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
RBC Capital Analyst forecast on DE:0VS
Luca Issi
RBC Capital
RBC Capital
€12.87
Buy
163.67%
Upside
Reiterated
07/30/26
Wave Life Sciences (WVE) Receives a Buy from RBC Capital
Canaccord Genuity Analyst forecast on DE:0VS
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€36.89
Buy
655.86%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR) and Wave Life Sciences (NASDAQ: WVE)
JonesTrading Analyst forecast on DE:0VS
Catherine Novack
JonesTrading
JonesTrading
€30.02
Buy
515.23%
Upside
Reiterated
05/19/26
Cantor Fitzgerald Analyst forecast on DE:0VS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
€11.15
Buy
128.51%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Gossamer Bio (NASDAQ: GOSS) and Cullinan Management (NASDAQ: CGEM)
Leerink Partners Analyst forecast on DE:0VS
Joseph Schwartz
Leerink Partners
Leerink Partners
€30.02→€21.45
Buy
339.45%
Upside
Reiterated
03/26/26
Leerink says Wave Life Sciences selloff 'very overdone' after early obesity dataLeerink says Wave Life Sciences selloff 'very overdone' after early obesity data
Jefferies Analyst forecast on DE:0VS
Roger Song
Jefferies
Jefferies
€24.02→€15.44
Buy
216.41%
Upside
Assigned
03/26/26
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Kodiak Sciences (NASDAQ: KOD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:0VS
Alec Stranahan
Bank of America Securities
Bank of America Securities
€14.58
Buy
198.83%
Upside
Reiterated
08/12/26
Alec Stranahan Maintains Buy Rating on Wave Life Sciences with Unchanged $17 Price Target Amid Multiple Clinical Catalysts
Mizuho Securities Analyst forecast on DE:0VS
Salim Syed
Mizuho Securities
Mizuho Securities
€23.16→€19.73
Buy
304.30%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Acurx Pharmaceuticals (NASDAQ: ACXP)
Mizuho Securities Analyst forecast on DE:0VS
Mara Goldstein
Mizuho Securities
Mizuho Securities
€30.88→€22.3
Buy
357.03%
Upside
Reiterated
08/03/26
Wave Life Sciences price target lowered to $26 from $36 at Clear StreetWave Life Sciences price target lowered to $26 from $36 at Clear Street
H.C. Wainwright Analyst forecast on DE:0VS
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€11.15
Buy
128.51%
Upside
Reiterated
07/31/26
Analyst Reiterates Buy on Wave’s WVE-007, Maintaining Unchanged $13 Price Target Amid Enhanced Phase 2a INLIGHT Design
Truist Financial Analyst forecast on DE:0VS
Danielle Brill
Truist Financial
Truist Financial
€12.87
Buy
163.67%
Upside
Reiterated
07/31/26
Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
B. Riley Securities Analyst forecast on DE:0VS
Madison Elsaadi
B. Riley Securities
B. Riley Securities
€26.59→€18.87
Buy
286.72%
Upside
Reiterated
07/31/26
B. Riley Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
Citi Analyst forecast on DE:0VS
Samantha Semenkow
Citi
Citi
€20.59→€16.3
Buy
233.98%
Upside
Reiterated
07/31/26
Wave Life Sciences price target lowered to $19 from $24 at CitiWave Life Sciences price target lowered to $19 from $24 at Citi
Wedbush Analyst forecast on DE:0VS
Yun Zhong
Wedbush
Wedbush
€12.87→€10.29
Buy
110.94%
Upside
Assigned
07/31/26
Wedbush Releases a Buy Rating on Wave Life Sciences (WVE)
Wells Fargo Analyst forecast on DE:0VS
Benjamin Burnett
Wells Fargo
Wells Fargo
€12.01
Buy
146.09%
Upside
Reiterated
07/30/26
Wells Fargo Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
RBC Capital Analyst forecast on DE:0VS
Luca Issi
RBC Capital
RBC Capital
€12.87
Buy
163.67%
Upside
Reiterated
07/30/26
Wave Life Sciences (WVE) Receives a Buy from RBC Capital
Canaccord Genuity Analyst forecast on DE:0VS
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€36.89
Buy
655.86%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR) and Wave Life Sciences (NASDAQ: WVE)
JonesTrading Analyst forecast on DE:0VS
Catherine Novack
JonesTrading
JonesTrading
€30.02
Buy
515.23%
Upside
Reiterated
05/19/26
Cantor Fitzgerald Analyst forecast on DE:0VS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
€11.15
Buy
128.51%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Gossamer Bio (NASDAQ: GOSS) and Cullinan Management (NASDAQ: CGEM)
Leerink Partners Analyst forecast on DE:0VS
Joseph Schwartz
Leerink Partners
Leerink Partners
€30.02→€21.45
Buy
339.45%
Upside
Reiterated
03/26/26
Leerink says Wave Life Sciences selloff 'very overdone' after early obesity dataLeerink says Wave Life Sciences selloff 'very overdone' after early obesity data
Jefferies Analyst forecast on DE:0VS
Roger Song
Jefferies
Jefferies
€24.02→€15.44
Buy
216.41%
Upside
Assigned
03/26/26
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Kodiak Sciences (NASDAQ: KOD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wave Life Sciences

3 Months
Joseph SchwartzLeerink Partners
Success Rate
9/20 ratings generated profit
45%
Average Return
+14.24%
Copying Joseph Schwartz's trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of +14.24% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
12/20 ratings generated profit
60%
Average Return
+20.66%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +20.66% per trade.
2 Years
Salim SyedMizuho Securities
Success Rate
20/45 ratings generated profit
44%
Average Return
+20.66%
Copying Salim Syed's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +20.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0VS Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
34
34
22
19
13
Buy
3
1
1
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
35
23
20
13
In the current month, 0VS has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0VS average Analyst price target in the past 3 months is 15.10.
Each month's total comprises the sum of three months' worth of ratings.

0VS Financial Forecast

0VS Earnings Forecast

Next quarter’s earnings estimate for 0VS is -€0.28 with a range of -€0.33 to -€0.19. The previous quarter’s EPS was -€0.29. 0VS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VS has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0VS is -€0.28 with a range of -€0.33 to -€0.19. The previous quarter’s EPS was -€0.29. 0VS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VS has Performed in-line its overall industry.

0VS Sales Forecast

Next quarter’s sales forecast for 0VS is €4.31M with a range of €0.00 to €17.12M. The previous quarter’s sales results were €1.94M. 0VS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VS has Performed in-line its overall industry.
Next quarter’s sales forecast for 0VS is €4.31M with a range of €0.00 to €17.12M. The previous quarter’s sales results were €1.94M. 0VS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VS has Performed in-line its overall industry.

0VS Stock Forecast FAQ

What is DE:0VS’s average 12-month price target, according to analysts?
Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 15.10.
    What is DE:0VS’s upside potential, based on the analysts’ average price target?
    Wave Life Sciences has 209.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Wave Life Sciences a Buy, Sell or Hold?
          Wave Life Sciences has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Wave Life Sciences’s share price target?
            The average share price target for Wave Life Sciences is 15.10. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €22.30 ,and the lowest forecast is €10.29. The average share price target represents 209.37% Increase from the current price of €4.88.
              What do analysts say about Wave Life Sciences?
              Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Wave Life Sciences?
                To buy shares of DE:0VS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.